ODN 1018 sodium
Based on 2 publication(s) in Google Scholar
ODN 1018 (1018 ISS) sodium is a TLR9 agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus.
For research use only. We do not sell to patients.
- Purity: 97.49%
- Molecular Weight:7150 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ODN 1018 sodium
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
|
TLR9 |
ODN1018 (0.7 μM) sodium stimulates proliferation and IL-6 production in purified human B cells, and this stimulation is inhibited by IRS at 0.35-0.7 μM[3].
ODN1018 (0.7 μM; 48 h) sodium activates mouse splenocytes to produce IL-6 via TLR9, and this activation is dose-dependently inhibited by IRS 869 at 0.0875-0.7 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
ODN 1018 (20 μg; intranasally; weekly; 1-17 weeks) sodium induces sustained suppression of allergic airway inflammation in ragweed-sensitized mice, with 5 weekly doses sufficient for durable effects associated with TReg induction[2].
ODN 1018 (50 μg; s.c.) sodium induces a lethal TLR9-mediated inflammatory response in D-galactosamine-pretreated BALB/c mice[3].
ODN 1018 (25 μg; s.c.) sodium stimulates TLR9-mediated cytokine (IL-6, IL-12) production in BALB/c mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (6-8 week old female, ragweed-sensitized allergic asthma model)[2]
-
Dosage:20 μg
-
Administration:intranasally; weekly; 1, 3, 5, 8, 12, 13, 16, or 17 weeks
-
Result:Suppressed bronchoalveolar lavage (BAL) eosinophilia, BAL IL-4, IL-5, IL-13 levels, and lung Th2-associated genes (Il13, Ccl11, Gob5, Fizz1) through 13 subsequent weekly ragweed exposures (12 weekly treatments).
Induced significant, lasting reduction of Th2-mediated responses (5 weekly treatments); Upregulated lung regulatory T cell (TReg)-associated genes (Foxp3, Il10, Tgfb1, Lag3, Tnfrsf4, Il2ra) and increased TReg activity (CD4+CD25+ T cells from treated mice suppressed CD4+CD25- T cell proliferation more effectively than those from ragweed-only mice) (16 weekly treatments).
Induced a moderate Th1 shift (progressive increase in lung Ifng, Cxcl9, Cxcl10 expression) but Th2 suppression did not require IFN-γ; Prevented ragweed-pulsed bone marrow dendritic cells from restoring Th2 responses.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Solid
-
Molecular Weight 7150 (free acid)
-
Color Off-white to light yellow
-
SMILES
[ODN 1018 (sodium)]
-
Synonyms
1018 ISS sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 May;641(8061):202-210. PMID: 40140567
ODN 1018 sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 May;641(8061):202-210. [Abstract]
Mice were immunized with ABM5-OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0 and 14.
ODN 1018 sodium purchased from MedChemExpress. Usage Cited in: Nature. 2025 May;641(8061):202-210. [Abstract]
Mice were immunized with ABM5-OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0 and 28.
-
J Ethnopharmacol
Elucidating the anti-HSV-2 mechanism of Longdan Xiegan Decoction via the TLR9 signaling pathway: A multi-omics perspective. [Abstract]2026 Jun 12:364:121470. PMID: 41791624
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2242 KB)
References
[1]. Friedberg JW, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 Aug;146(3):282-91. [Content Brief]
[2]. Eng NF, et al. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review. Hum Vaccin Immunother. 2013 Aug;9(8):1661-72. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz